It will be delivered in a unique applicator that allows surgeons to directly apply the waxy product on bleeding bones.
Wound Management Technologies (OTCQB:WNDM) announced its Resorbable Orthopedic Products (ROP) subsidiary has received FDA clearance for HemaQuell resorbable bone wax.
HemaQuell, which is based on a patent acquired in 2009, is a water soluble material used to control bleeding from bone surfaces.
It will be delivered in a unique applicator that allows surgeons to directly apply the waxy product on bleeding bones.
Unlike other non-resorbable “bone wax” the HemaQuell material is completely resorbed (re-absorbed) harmlessly into the body within a week and does not delay healing of bone injury.
Deborah Hutchinson, president of Wound Management Technologies, said: “We are extremely pleased to have this approval for HemaQuell.”
“HemaQuell will generate additional sales opportunities for our company in the operating room,” she added.
